Article >> Pharma Horizons V2/'18 >> Parenteral Drug Manufacturing Panel Discussion > Jason Bertola

May 03, 2018

How the Shift to Complex, Targeted Cancer Drugs is ReShaping Parenteral Drug Manufacturing

by Jason Bertola, Director, Global Highly Potent & Onology Platform, CPI

Article >> Chemistry Today Oligo Peptide Supplement, April 2018 > Dr. Matthieu Giraud

May 03, 2018

Oligonucleotide Development Trends:
Growing Interest in Oncology Therapies

by Dr. Matthieu Giraud, Director, Global Peptides, Oligonucleotides, Lipids & Carbohydrates Platform, CPI

CordenPharma Announces Commercial Oligonucleotide API Manufacturing Expansion in CordenPharma Colorado

May 01, 2018
CordenPharma is pleased to announce the expansion of new commercial Oligonucleotide API Manufacturing capabilities in our FDA inspected CordenPharma Colorado (Boulder, CO, USA) facility.

Presentation >> Key note speech at Pharma Congress 2018 > Continuous Manufacturing – Case Study

Apr 25, 2018
Presentation >> Key note speech at Pharma Congress 2018 > Continuous Manufacturing – Case Study given by Yves Michon, Managing Director, CordenPharma Chenôve (FR) > Read Presentation

Video >> Glatt @ CordenPharma Plankstadt: leading highly potent lab-scale containment technology

Apr 20, 2018
Video taken at CordenPharma Plankstadt highlighting Glatt's leading technology for highly potent laboratory scale containment pharma solutions.


Webinar >> by Robin Livingston > Critical Aspects of a Robust Highly Potent Compound Program

Apr 17, 2018

>> Register for the Webinar On Demand

Critical Aspects of a Robust Highly Potent Compound Program >> The Importance of Understanding Intangible Elements of Containment

by Robin Livingston, 
Environmental, Health & Safety Manager, CordenPharma Colorado

Live Webinar Given Wednesday, April 4, 2018 >>

8:00 MDT / 10:00 EDT / 16:00 EST

News >> CordenPharma Boulder Receives Successful FDA Inspection

Apr 04, 2018

CordenPharma is pleased to announce that in March 2018 our CordenPharma Boulder (CO, USA) manufacturing facility completed a general Inspection conducted by the US FDA. All Quality Systems were evaluated. The facility received a successful response with no FDA 483 observations reported. 

Event >> DCAT Week ’18: CordenPharma Outlines Integration of Former Pfizer API Facility

Apr 04, 2018
Jason Bertola, Director, Global Highly Potent & Oncology Platform, CordenPharma International, outlined CordenPharma's integration of a former Pfizer active pharmaceutical ingredient (API) manufacturing facility and plans for further expansion at the DCAT Week ’18 Member Company Announcement Forum, which was held Monday, March 19, 2018 in New York City.

Event >> CordenPharma Receives CMO Leadership Awards at DCAT 2018

Mar 28, 2018
CordenPharma Receives Life Science Leader CMO Leadership Awards for Quality, Reliability & Capabilities at a reception that took place on Wednesday, March 21st during DCAT 2018 in New York City. 

CordenPharma Announces Revamped Executive Leadership Team

Feb 13, 2018
CordenPharma is pleased to announce the appointments of Dr. Riku Heikki Rautsola as the new Chief Executive Officer & President, CordenPharma, Dr. Walter Kittl as its new Chief Operating Officer and as of May 2018, Heiko Serwe as its new Chief Financial Officer.  

Article >> C&EN Nov 13, 2017 > Interview with Dr. Michael Quirmbach at CPhI 2017

Dec 08, 2017
Dr. Michael Quirmbach comments on CordenPharma's recent acquisiton of CordenPharma Boulder in an interview with C&EN at CPhI 2017 entitled > Growth strategies for pharmaceutical chemical makers on display at CPhI.

Article >> Chemistry Today, Sept / Oct 2017 > by Dr. Matthieu Giraud & Christian Ahlmark

Nov 20, 2017
Article in Chemistry Today Sept / Oct 2017 > Oligonucleotides: Promising Therapeutics With Significant Challenges > by Dr. Matthieu Giraud & Christian Ahlmark

Article >> Pharma Horizon >> 5 Minutes at CPhI 2017 with Matthieu Giraud > CordenPharma

Nov 20, 2017
Pharma Horizon >> 5 Minutes at CPhI 2017 with Dr. Matthieu Giraud >> CordenPharma

Article >> Manufacturing Chemist, Nov 2017 >> Brian McCudden on new CordenPharma Boulder acquisition

Nov 20, 2017
Article >> Manufacturing Chemist, Nov 2017 >> Brian McCudden discusses new CordenPharma Boulder facility acquisition from Pfizer in Boulder, CO (US).

Article >> Success Factor - Containment >> Process Worldwide, June 2017 > by Axel Friese

Nov 14, 2017
A recent article covering CordenPharma Plankstadt's new, fully-contained development lab for highly potent compounds utilizing Glatt's containment solutions.

Article >> Serialization, European Pharma Manuf., Nov 2017 > by Mario Scigliano & Christian Ahlmark

Nov 03, 2017

A Fighting Chance: Looking at How a CDMO can Help with Global Serialisation Compliance

Packaging is integral to the fight against counterfeit medicines and serialisation of packaging is an essential tool with which companies and customers can use to verify drug products. Here, Mario Scigliano, serialisation & automation manager, and Christian Ahlmark, associate director, sales & key account management, CordenPharma, discuss how a CDMO can help give companies a fighting chance to be globally serialisation compliant.

CordenPharma Announces Strategic Investment in Small Molecule API Development Capacity

Oct 16, 2017
CordenPharma announces a strategic investment of €3.7 million in the manufacturing site infrastructure of CordenPharma Switzerland, located in Liestal, Switzerland. The investment will include an expansion of the square footage dedicated to Small Molecule, Peptide and Carbohydrate development services. 

CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder Colorado

Oct 10, 2017
CordenPharma announced it has entered into definite agreements to acquire the former Hospira Boulder (Colorado) high containment API site from Pfizer, Inc. The closing of the transaction is anticipated to occur in November 2017.

Webinar Archive >> by Dr. Iris Ziegler > Implementing a Quality by Design Development Philosophy

Oct 09, 2017

View Webinar Archive >>

Implementing a Quality by Design Development Philosophy >>
Benefits & Challenges in a Highly Potent Landscape

by Dr. Iris Ziegler, 
Director, Pharmaceutical Sciences & QbD, CordenPharma International

Live Webinar Given Wednesday, October 4, 2017

CordenPharma Inaugurates Third Development Suite for Highly Potent Oral Solid Dosage

Sep 13, 2017
CordenPharma is pleased to announce the completion of its newest early development suite for Highly Potent, oral solid dosage products in CordenPharma Plankstadt (DE). The new facility allows for the production of small batches, from 100g to approximately 1000g.

CordenPharma Latina US-FDA Warning Letter Closed

Aug 24, 2017
CordenPharma is pleased to announce that CordenPharma Latina, located near Sermoneta, Italy, has received news that the US-FDA warning letter previously received has been closed, with a closeout date of August 15, 2017. This success is the result of a holistic and systematic approach to remediate the observations throughout the facility.

CordenPharma to Invest €10 Million into New Manufacturing Line for Veterinary Drug Products

Aug 02, 2017
CordenPharma Plankstadt is pleased to announce the design and installment of a new manufacturing line dedicated to producing Veterinary Drug Products for 500kg scale batch sizes to supply a complex innovative product for application in the veterinary health market. This new line is part of a production plant that is dedicated to Veterinary Drug Products.

CordenPharma & GE Healthcare Offer Unique End-to-End Solution to Accelerate Oligonucleotide Drug Development

Jun 28, 2017
Two leaders in research and biopharma manufacturing enter a strategic collaboration to meet customer need for a simplified, faster development proces.
Chalfont St. Giles, UK and Plankstadt, Germany – June 28, 2017 – CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. 

Acasti Pharma & CordenPharma Announce Large Scale Production of CaPre with Continuous Manufacturing

Jun 01, 2017
Laval, Québec, CANADA – May 31, 2017 – Acasti Pharma Inc. (NASDAQ:ACST – TSX-V:ACST) today announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma. CaPre is a potentially best-in-class omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis. The process was jointly designed and implemented by the Acasti and CordenPharma technical teams and engineers at the CordenPharma Chenôve facility in Dijon, France. 

Video >> New Corden Pharma Colorado 2017 Video

May 16, 2017
View the new Corden Pharma Colorado 2017 Video, featuring peptide, highly potent and oligonucleotide API development and manufacturing.

CordenPharma Wins 2017 Life Science Leader CMO Leadership Awards Across All Award Categories

Mar 08, 2017
CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO), will be awarded 2017 CMO Leadership Awards presented by Life Science Leader magazine across all 6 Core Award Categories (including all 3 groups of Outsourcing Respondents) and all 8 Specialty Award Categories.

C&EN White Paper >> Minimizing Risk in API & Drug Product Development & Manufacturing

Nov 03, 2016
C&EN White Paper >>

Minimizing Risk in API & Drug Product Development
& Manufacturing >> A Fully Integrated Supply Chain

Brought to you by CordenPharma

CordenPharma Announces Completion of New Highly Potent API Process Bay for Category 4 Compounds

Oct 17, 2016
As part of a long term growth strategy designed to meet increasing customer demands, CordenPharma has completed a recent key investment to strengthen development and manufacturing capabilities for API offerings across its Highly Potent & Oncology Platform

Webinar >> by Dr. Stewart Campbell > Synthetic Carbohydrates as Targeting & Delivery Agents

Oct 16, 2016
View the Archive of a CordenPharma Webinar Organized by xTalks >>
Using Synthetic Carbohydrates as Biological Targeting & Delivery Agents 

>> by Dr. Stewart Campbell
Head of Business Development & Product Management, Carbohydrates, CordenPharma Switzerland / Woburn 
>> Live Webinar Given Wednesday, November 2, 2016 

>> Register for Archive Here

News >> CordenPharma Colorado Named Environmental Leader by CO State Health

Oct 15, 2016
An article in the Boulder Daily Camera on October 4, 2016 > Highlights CordenPharma Colorado as one of a dozen Boulder Valley companies to make the Colorado Department of Public Health and Environment's list of super-clean companies. CordenPharma Colorado is named Environmental Gold Leader.

Corden BioChem GmbH Announces New Pricing for 7-ACA

Sep 29, 2016
Today Corden BioChem GmbH announced that, starting October 1st 2016 and going forward, the minimum pricing for any new order of 7-ACA will be $60 USD/kg. Corden BioChem will no longer accept any orders below this base pricing.

CordenPharma Chenôve Receives Successful FDA Inspection

Aug 31, 2016
CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no 483s reported. The last FDA Inspection took place in 2014. 

Interview >> Dr. Michael Quirmbach >> A Decade of CordenPharma

Jul 25, 2016
Pharmaceutical Technology Interviews Dr. Michael Quirmbach, Vice President, Global Marketing & Sales, CordenPharma International >

A Decade of CordenPharma > From Inception to Full‑Service Provider

Interview >> EuroPeptides Interviews Dr. Mimoun Ayoub on Peptide Vaccines

Jul 20, 2016

EuroPEPTIDES, part of Tides Europe taking place November 14 - 17, 2016 in Berlin, Interviews Dr. Mimoun Ayoub, Director, Peptides, Lipids, Carbohydrates & Injectables Platforms on Peptide Vaccines.

CordenPharma Enters Oligonucleotide API Manufacturing Market

Jul 01, 2016
CordenPharma is pleased to announce its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing market in CordenPharma Colorado (USA) to further strengthen its CDMO offering.

CordenPharma Caponago Announces Successful Approval of New Sterile Injectable Facility

Jun 28, 2016
CordenPharma is pleased to announce the completion and approval of its aseptic filling line in CordenPharma Caponago (IT) by the Italian AIFA for clinical and commercial supply. 

Poster Abstract >> International Carbohydrate Symposium > by Dr. Stewart Campbell

Jun 21, 2016
View an abstract of the poster to be given at the International Carbohydrate Symposium, July 17-20, 2016 at the New Orleans Marriott, LA >> by Dr. Stewart Campbell, Head of Business Development & Product Management, Carbohydrates >> Title: Protection against experimental melioidosis with a synthetic beta-manno-heptopyranose hexasaccharide glycoconjugate

Event >> CordenPharma & Weylchem Run in Frankfurt J.P. Morgan Corporate Challenge

Jun 15, 2016
CordenPharma & Weylchem participated in the 2016 J.P. Morgan Corporate Challenge, which took place June 15th in Frankfurt, Germany. 

CordenPharma Latina Receives USFDA Warning Letter

May 27, 2016
CordenPharma International would like to notify customers about a warning letter received from the USFDA on May 24, 2016 in its CordenPharma Latina facility in Sermoneta, Italy. This action follows an earlier inspection of the site by the agency in May 2015. This matter is being considered throughout the organization with the utmost sense of urgency. 

Interview >> Ernesto Petroselli, President of CordenPharma > CEO Europe Magazine, June 2016

May 20, 2016

A Healthy Outlook

The pharmaceutical industry is booming, and global giant CordenPharma is well positioned to share in the spoils with its offering of a one-stop supply shop.

CordenPharma Arranges a Syndicated Loan of EUR 60 Million

May 02, 2016
ICIG’s CordenPharma Group today announced the closing of a syndicated loan of EUR 60 Million. CordenPharma successfully closed its first syndicated loan on advantageous terms. 

Article >> Chemistry Today Oligos & Peptides, March / April 2016 > by Dr. Mimoun Ayoub

Apr 22, 2016

Drug Conjugation > How Technology Drives the Supply Chain 

by Dr. Mimoun Ayoub
Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, CPI

Article >> Chemistry Today Oligos & Peptides, March / April 2016 >> by Dr. Stewart Campbell

Apr 22, 2016

Targeted Delivery of Nucleic Acids via Carbohydrate-Protein Interactions 

by Dr. Stewart Campbell
Head of Business Development & Product Management, Carbohydrates, CordenPharma Switzerland

Article >> Drug Development & Delivery, April 2016 > Luca Porcu Contribution

Apr 13, 2016
Read CordenPharma's article contribution titled CordenPharma: Full-Service Capabilities Geared to Meeting Aggressive Timelines from Luca Porcu, Director, Global Small Molecules Platform, in the Drug Development & Delivery April 2016 special feature on 'Outsourcing Formulation Development & Manufacturing: Using a Single Provider Reduces Costs & Risk'.

Caisson Establishes Global Manufacturing Partnership with CordenPharma

Apr 13, 2016
AUSTIN, Texas & OKLAHOMA CITY >> Caisson Biotech, LLC (Caisson), a leader in half-life extension and drug delivery, today announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma), a full-service Contract Development & Manufacturing Organization (CDMO) manufacturing APIs and Drug Products through a network of cGMP facilities across Europe and the US.

CordenPharma Announcements at DCAT Week '16 > Dr. Roberto Margarita

Apr 07, 2016
During the DCAT Member Forum on Monday, March 14, 2016 of DCAT Week '16 at the Waldorf Astoria in New York City, Dr. Roberto MargaritaDirector, Global Antibiotics, Highly Potent & Oncology Platforms, CPI, presented 4 CordenPharma announcements to the DCAT Community.

ICIG Completes Acquisition of Sandoz Site in Frankfurt-Höchst > Corden BioChem GmbH

Apr 01, 2016
International Chemical Investors Group (ICIG) today announced the completion of its acquisition of Sandoz Industrial Products GmbH, a Frankfurt-Höchst based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, from Novartis Group. Sandoz Industrial Products GmbH will be re-named Corden BioChem GmbH and will be associated with the CordenPharma Group, the pharma platform of ICIG. 

Video >> CordenPharma Plankstadt Expanded Highly Potent Development Facility

Mar 30, 2016

Click here to watch a video fo the newly expanded CordenPharma Plankstadt Highly Potent Development facility.

CordenPharma Announces Expanded Aseptic & Oral Development Capabilities

Mar 14, 2016
As part of a long term strategy to meet increasing customer demands, CordenPharma has completed two additional key investments to strengthen its development and manufacturing capabilities for Drug Product service offerings across its Highly Potent, Oncology and Injectables Platforms.

DCAT 2016 Interview Abstract >> Chemistry Today Jan-Feb 2016 >> Dr. Michael Quirmbach

Mar 03, 2016
Where do you see your company's role in the pharmaceutical supply chain?

With well-structured product & service offerings organized under the umbrella of six distinctive technology platforms – Peptides/Lipids/Carbohydrates, Injectables, Antibiotics, Highly Potent, Oncology and Small Molecules - CordenPharma is well-positioned as a key CDMO supplier and partner to the pharmaceutical industry. 

ICIG Acquires Sandoz Site in Frankfurt-Höchst

Feb 24, 2016
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement under which ICIG will acquire all of the shares in Sandoz Industrial Products GmbH, a Frankfurt-Höchst based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, especially for the use in antibiotics. Closing of the transaction is anticipated to occur on 1 April 2016.

News >> CordenPharma Colorado FDA Audit > Success

Feb 16, 2016
CordenPharma Colorado announces successful results from their recent 5 Day Intensive FDA Audit: no 483-observations and a No Action Indicated (NAI) status.

Interview >> IBC Interviews Tides 2016 Speaker Dr. Mimoun Ayoub

Feb 02, 2016
IBC interviews upcoming Tides 2016 Speaker Dr. Mimoun Ayoub, Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, on the role peptide vaccines play in the development of novel cancer therapies.

Orpegen Facility Moves to Frankfurt to become CordenPharma Frankfurt

Jan 25, 2016
Following the acquisition of ORPEGEN Peptide Chemicals GmbH on January 1, 2015, CordenPharma International announces that on July 1,2015, the non-GMP facility and personnel moved to a location in Frankfurt-Fechenheim now called CordenPharma Frankfurt.  

Video >> Optimising the Product-Performance Model > Panel at Pharma Integrates 2015

Dec 16, 2015
View the video of the Pharma Integrates 2015 panel discussion Optimising the Product-Performance Model with panelist Luca Porcu, Director, Global Highly Potent & Small Molecules Platforms

DCAT Annouces New Advisory Council Member Dr. Roberto Margarita

Oct 30, 2015
Robbinsville, NJ, USA > October 26, 2015 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Dr. Roberto Margarita, Director, Global Antibiotics & Oncology Platforms at CordenPharma International has been elected by the membership to serve on DCAT’s Advisory Council for a three-year term beginning November 1, 2015. 

Article >> Chimica Oggi, Sept 2015 > Critical Aspects of Robust Potent Compound Containment > by Amy Doane & Robin Livingston, CordenPharma Colorado

Oct 07, 2015
Amy Doane & Robin Livingston of CordenPharma Colorado discuss innovative solutions to ensure containment of Highly Potent Active Pharmaceutical Ingredients (HPAPIs).

Article >> Specialty Chemicals, Sept 2015 > Containing Highly Potent Ingredients > by Dr. Roberto Margarita & Luca Porcu

Oct 06, 2015
Dr. Roberto Margarita, Director of the Global Antibiotics & Oncology Platforms, and Luca Porcu, Director of the Global Highly Potent & Small Molecules Platforms, look at the many elements needed for a successful containment progamme.

CordenPharma Latina Approved for Clinical Supply of Sterile Oncology Lyophilised Products

Jul 13, 2015
CordenPharma is pleased to announce that the Sterile Oncology Suite in its CordenPharma Latina (IT) manufacturing facility has received approval for Clinical Supply of Sterile Oncology Lyophilised Products

Article >> Pharmaceutical Technology, June 2015 > Dr. Roberto Margarita Thought Leader Profile

Jul 06, 2015
Dr. Roberto Margarita, Director, Global Antibiotics & Oncology Platforms, CPI - Pharmaceutical Technology Thought Leader Profile - Resistance to Antibiotics is Driving A New Product Wave With Innovative Challenges.

Article >> CordenPharma Colorado Named in SafeBridge Potent Compound Certification Update

Jul 03, 2015
In a recent article in Manufacturing Chemist Pharma, CordenPharma Colorado was mentioned in an update by SafeBridge Consultants as a manufacturing organisation which continues to maintain effective performance in the recognition, evaluation and control of highly potent compounds.

ICIG Obtained EC Approval for Acquisition of Certain Chlorovinyls Assets Being Divested by INEOS

Jun 09, 2015
International Chemical Investors Group (ICIG) recently announced an agreement with INEOS and Solvay to acquire certain chlorovinyls assets being divested by INOVYN / INEOS. This agreement, which has been reviewed in the context of the merger control process of both this transaction and the INOVYN JV, has now received approval of the European Commission. The closing of the acquisition of the remedy business by ICIG is anticipated to be August 1, 2015.

Cover Story >> Chemica Oggi Peptide Supplement, April 2015 > by Dr. Mimoun Ayoub

May 11, 2015
Cover Story >> Peptide Vaccines: A Promising Therapeutic Approach. Addressing the CMC Challenges > Chemica Oggi Oligo & Peptide Supplement, April 2015 > by Dr. Mimoun Ayoub, Global Director, Peptides / Lipids / Carbohydrates & Injectables Platforms, CPI.

Article >> Chimica Oggi Peptide Supplement, April 2015 > Dr. Mimoun Ayoub Interview

May 09, 2015
Article >> The Expansion of the Therapeutic Applications of Peptides: Drivers & Challenges > Chimica Oggi Oligo & Peptide Supplement, April 2015 > Interview of Dr. Mimoun Ayoub, Global Director, Peptides / Lipids / Carbohydrates & Injectables Platforms, CPI.

Article >> EuroAsia Industry Magazine > Ernesto Petroselli Interview

May 08, 2015
Article >> Prospects Through Pharmaceutical Partnership > EuroAsia Industry Magazine, Issue 4/2015 > Interview by Ernesto Petroselli, Presdident, CordenPharma International.

Article >> Drug Development & Delivery, April 2015 > Dr. Roberto Margarita Contribution

May 08, 2015
Article >> Outsourcing Formulation & Manufacturing Development > Drug Development & Delivery, April 2015, Volume 15 > Contribution by Dr. Roberto Margarita, Global Director Antibiotics & Oncology Platforms, CPI

CordenPharma Wins 2015 CMO Industry Choice Award

Mar 18, 2015
CordenPharma is the winner of the 2015 Life Science Leader CMO Leadership Industry Choice Award for Big Pharma on March 18th at their awards ceremony in New York City.

Nanobiotix Appoints CordenPharma as Manufacturing Partner

Mar 18, 2015
Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces it has appointed CordenPharma as its manufacturing partner. 

CordenPharma Switzerland US Catalogue Order Processing Change

Mar 03, 2015
Effective March 5, 2015, CordenPharma Switzerland announces a transfer and change to the US Catalogue Product order process for small pack Phospholipids (1g and 10g) and Pseudoprolines (10g and 25g).

Peptisyntha Announces Successful FDA Inspection

Mar 02, 2015
Peptisyntha, a CordenPharma facility near Brussels, Belgium, announces a successful completion of their recent FDA inspection.

CordenPharma to Receive 9 Life Science Leader CMO Leadership Awards in 2015

Feb 19, 2015
On Wednesday March 18, 2015 CordenPharma will be recognized with 9 CMO Leadership Awards presented by Life Science Leader magazine. The Life Science Leader CMO Leadership Awards are determined through industry research conducted by Nice Insight.

CordenPharma Acquires the Assets of ORPEGEN Peptide Chemicals GmbH

Jan 16, 2015
On January 1, 2015 CordenPharma International acquired the assets of Orpegen Peptide Chemicals GmbH, located in Heidelberg, Germany, retaining both their experienced personnel and peptide capabilities. The newly acquired subsidiary, to be named CordenPharma Heidelberg, will provide innovative, cutting-edge process research and non-GMP development services. 

CordenPharma Plankstadt Announces Successful FDA Inspection

Oct 27, 2014
CordenPharma Plankstadt announces today successful results from their recent 5 day intensive FDA Inspection: no 483-observations were found and no recommendations were given.

CordenPharma Switzerland Transfers Amino Acid Building Blocks Portfolio to Chemie Uetikon GmbH

Feb 21, 2014
Effective February 1, 2014, CordenPharma Switzerland transfers their Amino Acid Building Blocks portfolio to Chemie Uetikon GmbH, based in Lahr, Germany

CordenPharma Colorado Receives Potent Compound Safety Certification Approval from SafeBridge®

Jan 27, 2014
CordenPharma Colorado announces receipt of approval for the "Potent Compound Safety Certification" by SafeBridge® Consultants, Inc. for the safe handling of potent APIs and compounds of unknown toxicity and potency.

CordenPharma Acquires Ancora's Carbohydrate Synthesis Platform

Nov 01, 2013
On October 31, 2013 CordenPharma acquired Ancora Pharmaceuticals, located in Woburn, MA, USA. Ancora’s unique carbohydrate synthesis technology platform and chemistry research facilities perfectly complement CordenPharma’s capabilities in the manufacture and supply of high-quality complex synthetic molecules. 

ICIG to acquire Allessa from Cassella

Sep 25, 2013

International Chemical Investors Group (ICIG) and Casella GmbH have reached an agreement in principle under which ICIG would acquire all of the shares of Allessa GmbH. Both parties have agreed not to disclose the purchase price.

CordenPharma Caponago Granted SHE Certification

Sep 03, 2013
CordenPharma Caponago was recently granted SHE Certification with an OH SAS 18001:2007 Certificate for the maintenance of their Safety Management System involving manufacturing activities and the packaging and control of injectable liquid, freeze-dried and powder products.

CordenPharma to Acquire Peptisyntha from Solvay

Aug 28, 2013
International Chemical Investors Group (ICIG) and the Solvay Group have entered into an agreement under which ICIG will acquire Peptisyntha SA, the Brussels, Belgium, based custom manufacturer of peptides for pharmaceutical use. Upon closing of the deal, expected later this fall, Peptisyntha will become a member of ICIG’s CordenPharma platform as its third site offering peptides manufacturing.

CordenPharma Colorado Boosts Boulder as Innovation Hub

Jun 13, 2013
In an article on June 7th of The Boulder County Business Report, the city of Boulder, Colorado was cited for national recognition as an innovation hub in various informal polls.

ICIG Announces New CordenPharma Management Team

Jun 03, 2013

ICIG announced today changes in the management of CordenPharma, its pharmaceutical contract manufacturing business.

What Does it Take to Produce 25 kg of Peptides?

May 06, 2013
Visit our upcoming poster Development of a Scalable Process for CNP-22, presented by Valerie Paulsen, Principal Analytical Chemist, CordenPharma Colorado at Tides 2013, May 12 - 15 in Boston.

Interview of CordenPharma Colorado's Brad DeHoff by Phenomenex

Apr 05, 2013
In a recent issue of their e-newslettter PrepLC eNews, the R&D staff at Phenomenex interviews Dr. Brad DeHoff, Director of R&D for CordenPharma Colorado, about current and future trends of the CMO industry.

ICIG kicks off €50+ million investment at PPC in Thann, France

Mar 22, 2013
International Chemical Investors Group (ICIG) kicks off €50+ million investment at PPC, a company of WeylChem Group, the fine chemicals platform of ICIG, to develop membrane-based technology. PPC is located in Thann, France.

CordenPharma Colorado Named Approved Peptide Supplier for Linaclotide

Mar 08, 2013

In an article published on March 4th in Chemical & Engineering News, CordenPharma Colorado was named an approved peptide supplier to Ironwood Pharmaceuticals for their product Linaclotide: 

CordenPharma Colorado Regional Science Fair 2013

Mar 05, 2013
On Thursday, February 28th CordenPharma Colorado sponsored and sent 3 scientists to serve as jurors for the CordenPharma Colorado Regional Science Fair, which took place at on the University of Colorado campus in Boulder.

CordenPharma Expands with ICIG Acquisition of Farchemia

Feb 13, 2013
CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.

CordenPharma Chenôve Receives Certificates from Japan PDMA and French ANSM

Dec 13, 2012
CordenPharma Chenôve receives updated certificate of compliance to cGMP standards from the PDMA in Japan and the ANSM in France.

CordenPharma Caponago Receives WCA Achievement Award

Nov 30, 2012
CordenPharma Caponago Receives Workplace Conditions Assessment (WCA) Achievement Award Enabled by Intertek.

Orifarm Generics Names CordenPharma Best Supplier

Oct 24, 2012
Today Orifarm Generics announced that CordenPharma was elected as the Best Supplier in the Orifarm Generics' Supplier Evaluation 2012.

CordenPharma Presents European Outsourcing Award at CPhI 2012

Oct 10, 2012
CordenPharma presents the award for the Most Effective Process Development/Scale-Up Programme at the European Outsourcing Awards on October 10th in Madrid during CPhI 2012. And the winner is....

Tessenderlo Group Intention to Sell Pharmaceutical Ingredients Activities

Oct 09, 2012
Tessenderlo Group (NYSE Euronext: TESB) announced today that it has the intention to sell its pharmaceutical ingredients activities, Farchemia and Calaire Chimie, to International Chemical Investors Group (ICIG), a private industrial holding company. The sale concerns two production sites in France and Italy.

CordenPharma Paclitaxel Approved in Europe

Oct 05, 2012
Today CordenPharma announced the approval of our proprietary generic drug product dossier for Paclitaxel in the reference state (Germany). With this approval CordenPharma is now open to out-licensing the generic Paclitaxel dossier with rights to register, promote and market the drug to esteemed customers in all EU territories.

CordenPharma to Sponsor Boulder Peptide Symposium 2012

Aug 09, 2012
CordenPharma will be Gold Sponsors of the Boulder Peptide Symposium, taking place September 26-28, 2012 at the St. Julien Hotel and Spa in Boulder, CO. Read the full story for Discounted Registration Information.

CordenPharma Colorado Named Among Top 50 Businesses in Boulder

Jul 31, 2012
In the Boulder Daily Camera's annual list of Top 50 Largest Businesses, CordenPharma Colorado ties with Google Inc. at Number 42 ~ click here for the Daily Camera's full article.

Frost & Sullivan Acclaims CordenPharma for Achieving Excellence in Product Differentiation

Feb 16, 2012
Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan recognises CordenPharma with the 2011 Western Europe Frost & Sullivan Award for Product Differentiation Excellence.

International Chemical Investors Group Announces Acquisition of CordenPharma Colorado from Roche

Oct 06, 2011
We are pleased to announce that on September 1, 2011 International Chemical Investors Group (ICIG) acquired a former division of Roche to join their pharmaceutical platform CordenPharma International as CordenPharma Colorado.

International Chemical Investors Group Announces Agreement to Acquire Pharmaceutical Intermediates Business from Genzyme Corporation

Feb 03, 2011
Luxembourg – International Chemical Investors Group (ICIG) announced that it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.